The supernatant lvas diluted 1:lOO with the buffered saline. All extracts lvere prepared fresh and used within 90 minutes. All runs contained the following controls: a positive serum of known titer, a negative serum, and a typical checkerboard of cross reactions between all reactants. If the test serum did not hemagglutinate heart-extract-sensitized tanned erythrocytes, then a test for the presence of inhibitors was performed by adding a constant volume of anti-heart positive serum to each tube of the negative test serum and the negative control serum series so that the tubes of the negative control series became positive. The tubes were shaken, the cells resuspended, and the test ~vas read after 2 hours. If inhibitors were present, the tubes containing higher concentrations of test serum suppressed hemagglutmation, whereas those containing lower concentrations did not. The titer of the inhibitor was taken as the dilution of the last tube in which hemagglutination was suppressed. Some of the sera which gave negative results on direct hemagglutination were incubated xvith positive anti-heart antiserum or with heart-extract-sensitized tanned red blood cells prior to repeating the test, in order to ascertain whether the site of action of the inhibition was with antibodies in the antiserum or with antigen on the erythrocytes or at both of these locations. Cross reactions with other organ extracts were studied with hemagglutination and hemagglutination-inhibition methods.
Results Table I presents the results of direct and inhibition hemagglutination tests performed on the serum of normal people and on that of patients with myocardial infarction.
The infarctions had occurred 9 days to 15 years earlier. The difference in the prevalence of positive hemagglutination tests between the group with myocardial infarction and the normal group is significant for both direct (p < O.OSj and inhibition (0.025 > p > 0.01) testing. Table II presents the data on serum hemagglutination tests in patients with various diseases. Direct hemagglutination occurred in cases of heart disease. Positive inhibition reactions occurred in patients lvith diseases which usually involve 1)lood vessels, e.g., lupus erythematosus, syphilitic aortitis, and pulmonary embolism.
TalJe III presents the results of tests for the presence of anti-heart hemagglutination inhibitors in sera which were ncgative for anti-heart antibodies by direct hemagglutination.
When the test sera were preincubated with the antigen-coated cells, the results were identical to those obtained Lvith the initial inhibition test. Inhibition occurred with the serum from one patient in the myocardial infarction group (No. S), and with that from the three persons in the normal group (Nos. 8, 9, and lo), regardless of whether prcincubation was with antigen-coated cells or anti-heart antiserum.
All four had titers of 1:128 or 1:256. Serum from Patients Nos. 2, 4, and 7 inhibited only after incubation with anti-heart antiserum. Table IV lists the hemagglutination test results with the intervals since the oldest and most recent infarctions. 
The sera of 29 per cent of the patients with myocardial infarction gave positive anti-heart hemagglutination tests, as compared to 6 per cent in the normal group (p < 0.005). This low frequency of positive tests in normal individuals has been report,yj.~,5z~~,ll
The prevalence of positive tests in the group with myocardial infarction compares favorably with the experience of others employing similar methods5f'jJ1 and precipitin procedures12 but is less than that observed with immunofluorescent techniques.lS Four of 5 patients with inactive rheumatic heart disease had positive anti-heart hemagglutination tests. This is similar to the frequency (92 per cent) reported by Zablocki.S Hess and Fink6 found 63 per cent positive results in patients with active rheumatic Am. Heart 3. Fcbwary, 1967 Tuble 11J. Intervals between anti-heart hemagglutination tests and myocardial iplufarction heart disease, but only 16 per cent in patients in whom the disease was in the inactive stage. Occasional reports of tests of the serum of individuals with "cardiomyopathy" have been included in papers on anti-heart serum factors1 Two of 5 such patients in this study had anti-heart antibodies.
These findings indicate a firm relationship between anti-heart serum hemagglutinins and structural heart disease, wit6 the former being more likely an effect than a cause of the heart disease, except, perhaps, in the case of acute rheumatic fever.7,14,1G There appears to be no clear relationship to a single pathologic change in the heart, since anti-heart hemagglutination reactions occurred in patients whose hearts were involved by acute or chronic inflammatory, degenerative, or necrotic processes, a situation also reported by others.Tb1hJ7 It would seem that these patignts are responding to a number of heart antigens by forming immunoglobulins that range from relatively nonspecific to cross reacting or highly speciiic.11J5~1*-z1 Serum from normal individuals and from patients with vascular or other cardiac diseases did not often give the positive anti-heart hemagglutination test results commonly encountered with serum from patients with myocardial infarction, rheumatic heart disease, or cardiomyopathy.
There was no association between the presence or titer of anti-heart hemagglutinins and the number of infarctions or the interval since infarction.
In rheumatic heart disease, cross-reacting antistreptococcal wall antibodies, as well as anti-heart factors, could be responsible for the positive tests observed. Anti-heart serum factors have been reported in lupus erythematosus and q~philis,~~~~~~~ but were not detected in this study. The serum in one case of inactive rheutnatoid arthritis produced hemagglutination at a titer of 1:16. Anti-heart hemagglutination inhibitors were more frequently encountered in the serum of patients with myocardial infarction than in that of normal subjects (Table  I) , but were observed in the serum of patients with cardiomyopathy, lupus erythematosus, syphilitic aortitis, pulmonary embolism, and pleurisy. Except for the case of pleurisy, they were not found in the absence of cardiac or vascular disease (Table II) .
Three types of anti-heart hemaggluti- 
